BioMedNewsBreaks Archive - Page 127 of 232

FridaySep 30, 2022 3:15 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Working to Make a Difference in Underserved Patient Populations

QSAM Biosciences (OTCQB: QSAM) is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “With the overall incidence of childhood cancer on the rise, the work of QSAM is becoming increasingly important… According to Children’s Cancer Cause, in 2022, an estimated 10,470 children (from birth to 14 years) and 5,480 adolescents (aged 15 to 19 years) will be diagnosed with cancer. ‘It is estimated that there will be 13.7 million cases of childhood cancer between 2020-2050. Unless there are major improvements in diagnosis and…

FridaySep 30, 2022 11:05 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of common stock, each at a public offering price of $5.00. Silo Pharma’s common stock began trading on the Nasdaq Capital Market on Sept. 27, 2022, under the symbol SILO. The company secured $5,750,000 million in gross proceeds from the offering, before deducting underwriting discounts and…

ThursdaySep 29, 2022 1:58 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Announces Participation in Two Investor Events

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will be attending and presenting at two upcoming investor conference: the Dawson James Small Cap Growth Conference and The ThinkEquity Conference. Slated for Oct. 12, 2022, the Dawson James event will be held in Jupiter, Florida. HeartBeam founder and CEO Branislav Vajdic, PhD, will be joined by chief financial officer Rick Brounstein and chief business officer Jon Hunt, PhD, at the conference to deliver the company’s presentation and also meet one-on-one with meeting attendees. The presentation is…

ThursdaySep 29, 2022 12:36 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced its receipt of confirmation from the Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). In addition, Nasdaq confirmed that Aditxt meets the stockholders’ equity requirement in Listing Rule 5550(b)(1) and all other applicable criteria for continued listing. Amro Albanna, co-founder, chairman and CEO of Aditxt, said that the company’s recent completion of a reverse stock split…

WednesdaySep 28, 2022 2:04 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, the first European clinical trial sites in France and Spain are now open and actively enrolling patients. “Our primary focus continues to be on advancing the clinical development of…

WednesdaySep 28, 2022 1:29 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion of all cohorts for its Phase I Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) clinical trial. Odyssey’s trial involved administering its novel drug to treat concussion, PRV-002, to healthy human subjects. The drug was safe and well tolerated throughout the trial. “After reviewing the data from each of the cohorts, I have strong confidence that it is safe to proceed to the next clinical trial phase where PRV-002 will be administered for 10 consecutive days to subjects following concussion,” said Dallas…

WednesdaySep 28, 2022 12:08 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Technology Enabling 12-Lead ECG Receives Patent from USPTO

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been granted a patent from the United States Patent and Trademark Office (“USPTO”). The patent covers proprietary technology that allows the HeartBeam AIMIGo(TM) credit card-sized device to enable a 12-lead ECG anytime or anywhere. According to the announcement, the innovative tech and AIMIGo device makes it possible for a patient to record signals outside of a medical setting with a diagnostic synthesized 12-lead ECG that is immediately transmitted to a physician for review and diagnosis; the now-patented…

WednesdaySep 28, 2022 11:37 am

BioMedNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Featured in ‘Psychedelics Tonight’ Docuseries

Universal Ibogaine (TSX.V: IBO) (“UI”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, announced it has been featured in a documentary series, which was co-produced by Kyle Buller and Joe Moore of Psychedelics Today in partnership with ALTRD.TV. Entitled Psychedelics Tonight, the docuseries provides information on the history and future potential of several psychedelic compounds including iboga and ibogaine. The first episode of the series aired on Monday, Sept. 26, 2022. “We are excited to see a growing variety of media channels pick up the story of ibogaine, to help educate the public and the…

TuesdaySep 27, 2022 3:06 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. The company today provided shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering. “Aditxt’s key to success is multifaceted and tied to the success of each of the company’s programs, which currently include AditxtScore(TM), Adimune(TM) and Adivir(TM). The successful completion of the reverse stock split and the closing of our public offering were critical to continuing the progress within each of these programs toward commercialization, and…

TuesdaySep 27, 2022 2:30 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its wholly owned subsidiary, Cybin IRL Limited, have signed a deal with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement for the license will provide access to large catalog of compounds that are complementary to Cybin’s preclinical assets and that strengthen the company’s drug-discovery and development platform to build future potential novel drug candidates. The agreement also supports Cybin’s broad intellectual property portfolio of innovative psychedelic-based molecules. According to…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Working to Make a Difference in Underserved Patient Populations

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Announces Participation in Two Investor Events

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Technology Enabling 12-Lead ECG Receives Patent from USPTO

BioMedNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Featured in ‘Psychedelics Tonight’ Docuseries

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search